We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » In Watershed Moment, FDA Approves Biogen’s Aducanumab for Alzheimer’s
In Watershed Moment, FDA Approves Biogen’s Aducanumab for Alzheimer’s
Despite an unconvinced advisory committee panel and accusations that the FDA worked too closely with Biogen on its Alzheimer’s drug aducanumab, the agency on Monday moved to OK the drug under accelerated approval in a long-awaited decision for patients with the degenerative neurological illness.